Specifically, EVs EGFR, as a special membrane surface marker, has a promoting effect in tumour progression and metastasis, and targeting EGFR may be therefore a promising strategy for improving the therapeutic outcome and prognosis of cancer patients. The gene discussed is EGFR; the disease is neoplasm.